Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform
Open Access
- 16 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 9 (12), e015628
- https://doi.org/10.1161/jaha.119.015628
Abstract
Background Interleukin 6 concentration is associated with myocardial injury, heart failure, and mortality after myocardial infarction. In the Norwegian tocilizumab non–ST‐segment–elevation myocardial infarction trial, the first randomized trial of interleukin 6 blockade in myocardial infarction, concentration of both C‐reactive protein and troponin T were reduced in the active treatment arm. In this follow‐up study, an aptamer‐based proteomic approach was employed to discover additional plasma proteins modulated by tocilizumab treatment to gain novel insights into the effects of this therapeutic approach. Methods and Results Plasma from percutaneous coronary intervention–treated patients, 24 in the active intervention and 24 in the placebo‐control arm, drawn 48 hours postrandomization were randomly selected for analysis with the SOMAscan assay. Employing slow off‐rate aptamers, the relative abundance of 1074 circulating proteins was measured. Proteins identified as being significantly different between groups were subsequently measured by enzyme immunoassay in the whole trial cohort (117 patients) at all time points (days 1–3 [7 time points] and 3 and 6 months). Five proteins identified by the SOMAscan assay, and subsequently confirmed by enzyme immunoassay, were significantly altered by tocilizumab administration. The acute‐phase proteins lipopolysaccharide‐binding protein, hepcidin, and insulin‐like growth factor‐binding protein 4 were all reduced during the hospitalization phase, as was the monocyte chemoattractant C‐C motif chemokine ligand 23. Proteinase 3, released primarily from neutrophils, was significantly elevated. Conclusions Employing the SOMAscan aptamer‐based proteomics platform, 5 proteins were newly identified that are modulated by interleukin 6 antagonism and may mediate the therapeutic effects of tocilizumab in non–ST‐segment–elevation myocardial infarction.This publication has 40 references indexed in Scilit:
- Hepatic acute phase proteins – Regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signalingEuropean Journal of Cell Biology, 2012
- Hepcidin Destabilizes Atherosclerotic Plaque Via Overactivating Macrophages After ErythrophagocytosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysisThe Lancet, 2012
- Successful Use of Tocilizumab in a Patient With Rheumatoid Arthritis Following Severe Pancytopenia During Etanercept TherapyJCR: Journal of Clinical Rheumatology, 2011
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker DiscoveryPLOS ONE, 2010
- Expression of the peptide hormone hepcidin increases in cardiomyocytes under myocarditis and myocardial infarctionThe Journal of Nutritional Biochemistry, 2010
- Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion developmentAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Genetic Deletion of Pregnancy-Associated Plasma Protein-A Is Associated With Resistance to Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice Challenged With a High-Fat DietCirculation Research, 2007
- Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardiumMolecular and Cellular Biochemistry, 1995